General Hospital Psychiatry
Volume 32, Issue 1 , Pages 108-110 , January 2010

Fluoroquinolone-induced suicidal ideation

  • Elizabeth A. LaSalvia, M.D.

      Affiliations

    • Department of Psychiatry, Brigham and Women's Hospital, Boston, MA 02115, USA
    • ,
  • Gretchen J. Domek, B.A.

      Affiliations

    • Harvard Medical School, Boston, MA 02115, USA
    • ,
  • David F. Gitlin, M.D., F.A.P.M.

      Affiliations

    • Harvard Medical School, Boston, MA 02115, USA
    • Department of Psychiatry, Brigham and Women's/Faulkner Hospitals, Boston, MA 02115, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Brigham and Women's Hospitals, Boston, MA 02115, USA. Tel.: +1 617 732 6701.

Received 13 November 2008 ,Accepted 3 March 2009.

References 

  1. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769–2802
  2. Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci A, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials. Drug Safety. 2003;26:109–120
  3. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47(Suppl 3):9–14
  4. Christ W. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother. 1990;26(Suppl. B):219–225
  5. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett. 2002;127:269–277
  6. Ortho-McNeil Pharmaceutical, Inc. Levaquin Product Insert.
  7. James EA, Demian AZ. Acute psychosis in a trauma patient due to ciprofloxacin. Postgrad Med J. 1998;74:189–190
  8. McCue JD, Zandt JR. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med. 1991;90:528–529
  9. Mulhall JP, Bergmann LS. Ciprofloxacin-induced acute psychosis. Urology. 1995;46:102–103
  10. Zaudig M, Von Bose M, Weber M, Bremer D, Zieglgansberger W. Psychotoxic effects of ofloxacin. Pharmacopsychiatry. 1989;22:11–15
  11. Akhtar S, Ahmad H. Ciprofloxacin-induced catatonia. J Clin Psychiatry. 1993;54:115–116
  12. Kushner J, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother. 2001;35:1194–1197
  13. Farrington J, Stoudemire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiologies. Gen Hosp Psychiatry. 1995;17:47–53
  14. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics past, present, and future. Drug Safety. 1995;13:343–358
  15. Lode H. Potential interactions of the extended-spectrum fluoroquinolones with the CNS. Drug Safety. 1999;21:123–135
  16. Domagala JM. Structure–activity and structure–side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994;33:685–706
  17. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother. 2007;41:1859–1866
  18. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144–S157
  19. Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U. Possible interaction of fluoroquinolones with the benzodiazepine–GABA-receptor complex. Br J Clin Pharmacol. 1990;30:63–70
  20. Sanacora G, Saricicek A. GABAergic Contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets. 2007;6:127–140
  21. Christ W, Gindler K, Gruene S, Hecker W, Jacobsen M, Junge H, et al. Interactions of quinolones with opioid and fenbufen, a nonsteroidal anti-inflammatory drug: involvement of dopaminergic neurotransmission. Rev Infect Dis. 1989;11(suppl 5):S1393–S1394
  22. Feinberg SS. Fluoroquinolone-induced depression. Am J Psychiatry. 1995;152:954–955
  23. Stahlmann R, Lode H. Fluoroquinolones in the elderly. Drugs Aging. 2003;20:289–302
  24. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets. 2007;6:101–115
  25. Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol. 2008;75:997–1006
  26. Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets. 2007;6:87–100
  27. Hall CE, Keegan H, Rogstad KE. Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. Int J STD AIDS. 2003;14:636–637
  28. Jick SS, Vasilakis C, Martinez C, Jick H. A study if the relation of exposure to quinolones and suicidal behavior. Br J Clin Pharmacol. 1998;45:77–81
  29. Patten SB. Non-psychiatric therapeutic medications in the etiology of organic depression. Psychiatr J Univ Ott. 1990;15:150–155
  30. Patten SB, Love EJ. Drug-induced depression incidence, avoidance, and management. Drug Safety. 1994;10:203–219
  31. Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom. 1997;66:63–73
  32. Patten SB, Lamarre CJ. Can drug-induced depressions be identified by their clinical features?. Can J Psychiatry. 1992;37:213–215
  33. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245
  34. Grassi L, Biancosino B, Pavanti M, Agostini M, Manfredini R. Depression or hypoactive delirium? A report of ciprofloxacin-induced mental disorder in a patient with chronic obstructive pulmonary disease. Psychother Psychopharm. 2001;70:58–59
  35. Wambulwa C, Bwayo S, Laiyemo AO, Lombardo F. Trimethoprim-sulfamethoxazole-induced aseptic meningitis. J Natl Med Assoc. 2005;97:1725–1728
  36. Saidinejad M, Ewald MB, Shannon MW. Transient psychosis in an immune-competent patient after oral trimethoprim-sulfamethoxazole administration. Pediatrics. 2005;115:e739–e741
  37. Saxe TG. Severe depression from TMP-SMX. Drug Intell Clin Pharm. 1998;22:267

PII: S0163-8343(09)00048-6

doi: 10.1016/j.genhosppsych.2009.03.002

General Hospital Psychiatry
Volume 32, Issue 1 , Pages 108-110 , January 2010

Article Tools